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Abstract.  Suppression of apoptosis has been impli- 
cated as a mechanism for the hepatocarcinogenicity of 
the peroxisome proliferator class of non-genotoxic car- 
cinogens. The ability of the peroxisome proliferator 
nafenopin to suppress or delay the onset of liver apop- 
tosis was investigated using primary cultures of rat he- 
patocytes and the Reuber hepatoma cell line FaO.  50 
~M nafenopin reversibly maintained the viability of 
primary rat hepatocyte cultures which otherwise de- 
generated within 8 d of establishment. The main- 
tenance of viability of hepatoeyte monolayers was as- 
sociated with a significant decrease in the number of 
cells exhibiting chromatin condensation patterns typi- 
cal of apoptosis.  Apoptosis could be induced in hepa- 
tocytes by administration of 5 ng/ml TGFBt.  Co- 
addition of 50/~M nafenopin significantly reduced 
TGFBt-induced apoptosis by 50-60%. 
TGFBI  (1-5 ng/ml) also induced apoptosis in the 
FaO rat hepatoma cell line. Cell death was accompa- 
nied by detachment of FaO cells from the monolayer 
and detached cells exhibited chromatin condensation 
and non-random DNA fragmentation patterns typical 
of apoptosis.  Co-addition of 50/~M nafenopin to 
TGFBl-treated FaO cultures significantly reduced the 
number of apoptotic cells detaching from the 
monolayer at 24 h. In contrast, nafenopin had no 
significant effect on FaO apoptosis induced by the 
DNA damaging agents etoposide and hydroxyurea. 
We conclude that suppression of liver cell death by 
apoptosis may play a role in the hepatocarcinogenicity 
of the peroxisome proliferators, although the extent of 
this protection is dependent on the nature of the apop- 
totic stimulus. 
T 
HE hypolipidemic drug nafenopin is one of a diverse 
group of non-genotoxic carcinogens termed peroxi- 
some proliferators (19) that cause hepatic peroxisome 
proliferation and liver enlargement in  rodents (20,  14). 
These changes are accompanied by the elevated transcrip- 
tion of genes encoding the microsomal enzyme cytochrome 
P451MA1 (17) and the peroxisomal enzymes of B-oxidation, 
acyl-CoA oxidase, and peroxisomal bifunctional enzyme  (11, 
15). More importantly, despite their apparent lack of geno- 
toxic activity, the peroxisome proliferators are potent rodent 
liver carcinogens (7, 26).  Since the molecular mechanisms 
responsible  for peroxisome proliferator-induced hepatocar- 
cinogenesis are not yet defined, the risk posed to man by this 
diverse group of compounds cannot yet be assessed. 
A number of mechanisms have been proposed to explain 
the hepatocarcinogenicity of the peroxisome proliferators 
(reviewed in 14, 18). The peroxisome proliferator-activated 
receptor is activated by these chemicals and as a result has 
been implicated in the carcinogenic  process (9, 10, 25). It has 
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also been suggested that excess hydrogen  peroxide, produced 
as a result of  increased peroxisomal activity, may cause DNA 
damage in bepatocytes  by oxidative  stress  (21). The sus- 
tained replicative  DNA synthesis  induced by peroxisome 
proliferators in  hepatocytes could act to  promote DNA- 
damaged hepatocytes and other previously  initiated  cells 
(13).  Complementary to  sustained  proliferation,  another 
factor in peroxisome proliferator-induced hepatocarcino- 
genesis may be the suppression or retardation of hepatocyte 
apoptosis (programmed cell death), allowing the survival of 
potentially tumorigenic cells that would otherwise be elimi- 
nated (5). Evidence in support of the latter hypothesis has 
been obtained from in vivo studies  (3, 4, 23):  other non- 
genotoxic carcinogens  such as cyproterone acetate or phe- 
nobarbital  induce liver cell hyperplasia  in  rodents (23). 
Withdrawal of these compounds causes  regression of the 
hyperplastic liver with a concomitant increase in cell death 
by apoptosis.  This liver regression is reversible and can be 
inhibited by readministration  of the relevant compound (3). 
Interestingly, the apoptosis that follows withdrawal of cypro- 
terone acetate can  also  be  inhibited  by  the peroxisome 
proliferator nafenopin (4). While these results indicate that 
nafenopin may suppress apoptosis in the liver, there is as yet 
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the hepatocarcinogenicity  of the peroxisome proliferators. 
In  order  to  address  this  important  question,  quantitative 
analysis of the ability of peroxisome proliferators-to modu- 
late liver cell apoptosis is required. 
Apoptotic cells in vivo are rapidly recognized and phago- 
cytosed by neighboring  cells (8).  Moreover, in contrast to 
necrosis, apoptosis occurs in single cells scattered through- 
out the organ and only a relatively small number of cells are 
detectable as apoptotic at any one time (8). Taken together, 
these factors make it difficult to quantify satisfactorily the 
amount of apoptosis occurring in the liver in vivo. 
Primary rat hepatocytes degenerate rapidly following their 
isolation and only survive in culture for a limited period of 
time (22). We and others have shown that exposure of these 
hepatocyte  cultures  to  nafenopin  can  reversibly  maintain 
their viability. In this paper we present the results of experi- 
ments designed to determine whether this maintenance  of 
hepatocyte viability is a result of suppression of hepatocyte 
apoptosis.  In light of recent reports  that  the liver growth 
regulator TGF31  induces apoptosis in primary hepatocytes 
and a number of cell lines in vitro (12, 16, 27), we have also 
examined  the  ability  of nafenopin  to  protect  hepatocytes 
from TGF31-induced cell death. 
We have performed complementary studies of the effect of 
nafenopin on liver apoptosis using the FaO hepatoma cell 
line, since these cells are easier to manipulate in culture than 
primary hepatocytes. We previously validated FaO as a suit- 
able  model  system for this  application  since it  expresses 
markers of differentiated liver function, responds to nafeno- 
pin via induction of cytochrome P4504A1 and readily under- 
goes apoptosis in response to a number of stimuli (1). Here 
we have investigated whether nafenopin also protects FaO 
cells  from  apoptosis  induced  by  TGF/31. To  address  the 
question of whether nafenopin prolongs cell survival regard- 
less of the cell death stimulus, we have also investigated the 
effects of co-addition of nafenopin with the DNA damaging 
cytotoxic agents etoposide and hydroxyurea. 
Materials and Methods 
Materials 
Nafenopin  (2-methyl-2-  [1,2,3,4-(tetrahydro-l-napthyl)-phenoxyl]prionic 
acid) was a gift from Ciba-Geigy (Basel, Switzerland). TGF31  from hu- 
man platelets was  from Sigma (Poole,  UK).  Acridine orange,  Hoechst 
33258,  and ethidium bromide were from Molecular Probes Inc. (Junction 
City, Oregon). Ham's Nutrient Mixture F12 was from Imperial Laboratories 
(Andover, UK) and all other tissue culture reagents were purchased from 
Gibco Ltd. (Uxbridge, UK). All other chemicals were from Sigma (Poole, 
UK). FaO cells were a gift from Dr. Mary Weiss (Pasteur Institute, Paris). 
Preparation of  Primary Hepatocyte Cultures 
Rat hepatocytes were isolated from  180-200  g  male Alderley Park rats 
(Wistar derived) by a two stage collngenase perfusion method as described 
previously (24). Briefly, livers of rats under terminal anaesthesia were per- 
fused with 0.05 % eollagenase and a bepatocyte suspension was obtained by 
passing digested livers through a 0.125  mm gauze. Cells were washed in 
Hanks balanced salt solution and cell viability was determined by trypan 
blue exclusion. Approximately 400 million cells were obtained per liver 
with a viability of ~85 %. 
Culture of  Primary Hepatocytes 
1.8  ×  106 freshly isolated bepatocytes were seeded into 25 cm  3 flasks in 
4 ml Williams E medium supplemented with 10% foetal bovine serum (heat 
inactivated), 10 t~g/ml insulin, 0.1 t~M hydrocortisone, 2 mM L-glutamine, 
100 U/ml penicillin, and 100/~g/ml streptomycin. Flasks were pre-coated 
with rat tall collagen to aid attachment of  hepatocytes. Cultures were main- 
talned at  37°C  in a  humidified atmosphere of 5%  CO2.  Medium was 
changed 4, 24, and every 48 h after seeding. 
Culture of  FaO Hepatoma Cells 
FaO cells were cultured in Ham's Nutrient Mixture FI2 supplemented with 
10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 
#g/ml streptomycin. Cells were routinely seeded at 1  x  106 cells/75 cm  3 
flask in 10 ml medium on day 0 and passaged every 5 d by trypsinization. 
Cells were maintained at 37"C in a humidified atmosphere of 5 % COz and 
medium was changed every 48 h. 
Assessment of  CeU Viability  by Trypan Blue Exclusion 
Equal  volumes of cell suspension and trypan blue  (0.3%  in phosphate 
buffered saline) were mixed and cell counts were performed on a hemo- 
cytometer. At least 100 cells were counted per data point. Viable cells were 
identified as those which excluded trypan blue and were expressed as a per- 
centage of total cell number. 
Analysis of  Hepatocyte Nuclear  Morphology 
Primary hepatocyte monolayers were fixed in ice cold methanol/acetic acid 
(3:1) for 5 rain. Cells were then stained with Hoechst 33258  (5/~g/ml in 
H20) for 10 rain and washed in distilled water. Cells were mounted in a 
solution of 20 mM citric acid, 50 mM di-sodium orthophosphate, and 50% 
glycerol (pH 5.5) to achieve optimum fluorescence and were examined at 
a wavelength of 350-460 nm using an Olympus microscope with fluores- 
cence attachment. 10 randomly chosen fields, representing at least 800 cells 
were analyzed for each data point. Apoptotic cells were identified as those 
with brightly staining condensed chromatin and were expressed as a per- 
centage of total cell number. 
Analysis of  FaO Nuclear  Morphology 
The morphology of detached and attached FaO cells was examined by acri- 
dine orange staining and fluorescence microscopy as described previously 
(1). Briefly a 6/~1 sample of cell suspension was mixed on a slide with an 
equal volume of acridine orange solution (10 ttg/ml in phosphate buffered 
saline). Green fluorescence was detected between wavelengths 500-525 nm 
using an Olympus microscope with fluorescence attachment.  Apoptotic 
cells were identified as those with brightly staining condensed nuclei and 
were expressed as a percentage of total cell number. Images were recorded 
using a Biorad MRC 600 confocal microscope. 
Analysis of DNA Integrity by Agarose 
Gel Electrophoresis 
The DNA from attached and detached PaO cells was analyzed by agarose 
gel  electrophoresis as  described previously (1). Briefly,  106  cells were 
pelleted at 174 g and resuspended in 20 ~1 lysis buffer (10 mM EDTA, 50 
mM Tris/HC1  containing 0.5% sodium lauryl sarkosinate, and 0.5 mg/ml 
proteinase K). 10 #1 low gelling temperature agarose, melted at 70°C, was 
added before loading the samples onto a  2%  agarose gel containing 10 
/~g/mi ethidium bromide. The gel was flooded with tris-phosphate-EDTA 
running buffer and DNA was subjected to electrophoresis at 40 V for 3 h. 
The gel was then incubated for 3 h with TPE running buffer containing 0.1 
m~/ml RNase and DNA was visualized under UV epi-ilhimination. 
Treatment of CeUs with Nafenopin 
Nafenopin was added to the medium of primary hepatocytes and FaO cells 
from a  20 mM stock dissolved in dimethylformamide (DMF) 1.  Control 
flasks were treated with DMF to the same final concentration of 0.25% 
vol/vol. 
Treatment of CeUs with TGF3 
Freshly isolated hepatocytes were seeded as described above. FaO cells 
were seeded at 3  x  105 cells/25 cm  3 flask in 4 ml Ham's F12 medium con- 
taining 10%  charcoal-stripped serum. After 24 h, cells were washed and 
1. Abbreviation  used in this paper:  DME dimethylformamide. 
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taining 0.2%  BSA. After a further 24 h  1 ng/rnl or 5  ng/ml TGF/31 was 
added from a 2 #g/ml stock in 4 mM HCI. Control flasks were treated with 
HC1 to the same final concentration of 0.1% vol/vol. The viability of pri- 
mary  bepatocytes was  analyzed 24  and 48  h  after  TGF/3~ addition by 
Hoechst 33258 staining. FaO cell viability was assessed daily over 3 d after 
TGFfll addition by trypan blue exclusion, acridine orange staining of nu- 
clear  morphology, and  gel  electrophoresis of DNA  from  attached  and 
detached cells. 
Treatment of  FaO Cells with VP-16  and Hydroxyurea 
FaO cells were seeded at  l  x  105 cells/25 cm  3 flask in 4  ml complete 
Ham's F12  medium. 24 h  after seeding, 50 #M nafenopin or DMF was 
added After a further 24 h,  10 #M VP-16 (from a 4 mM stock in DMF) 
or 1 mM hydroxyurea (from a 100 mM stock in Ham's F12 medium) were 
added. Cell viability was assessed  daily for 3 d after drug addition by trypan 
blue exclusion, acridine orange staining of nuclear morphology and gel 
electrophoresis of DNA from attached and detached cells. 
Statistical Analysis of  Results 
The statistical significance of the difference between the mean results of at 
least three independent  experiments was calculated using the Students t test. 
Results 
Maintenance of  Hepatocyte Viability by Nafenopin 
Primary bepatocyte cultures degenerated by approximately 
8 d after their establishment. Analysis of degenerating hepa- 
tocyte monolayers by light microscopy revealed that hepato- 
cytes lost their regular polygonal shape, increased their num- 
ber of nuclei and detached from the monolayer (Fig.  1 a). 
The viability of hepatocyte cultures was maintained by the 
addition of 50 #M nafenopin to the culture medium (Fig.  1 
b). Hepatocyte viability was maintained for at least 6 wk but 
withdrawal of nafenopin from the cultures lead once again 
to the onset of degeneration and cell death about 8 d later 
(Fig.  1 c). 
Effect of  Nafenopin on Hepatocyte Apoptosis 
Fluorescence microscopy of fixed hepatocyte monolayers 
stained with Hoechst 33258  was used to enumerate cells 
with chromatin condensation patterns typical of apoptosis. 
In the absence of nafenopin, apoptotic cells were detected in 
hepatocyte monolayers as early as 24 h after isolation and 
were detected at levels of  0.5-1% of  total cell number on each 
of the following 8 d (Fig. 2 a).  In six independent experi- 
ments, the number of apoptotic cells counted in nafenopin- 
treated hepatocyte cultures during the 8 d after establishment 
was significantly  lower (P < 0.1) than the number seen in un- 
treated controls (Fig. 2 b). 
Effect of Nafenopin on TGFflrinduced 
Hepatocyte Apoptosis 
Exposure of serum-free primary hepatocyte cultures to 1-5 
ng/ml  TGF~/t for  48  h  resulted  in  apoptotic  cell  death. 
Treatment with 5 ng/ml TGF/3~ caused a significant five- to 
six-fold increase in the number of apoptotic cells detected 
above levels seen in untreated controls  (P <  0.001). The 
"I'GF/31 solvent, HC1, had no significant effect on cell viabil- 
ity. Co-addition of 50 aM nafenopin to cultures treated with 
TGF/3~ (5 ng/ml) significantly reduced by 40 and 75 % the 
number of apoptotic cells counted after 24 and 48 h, respec- 
tively (P < 0.1, Fig. 3). The addition of the nafenopin solvent 
DMF had no significant effect on apoptotic cell number. 
Figure 1. (a) Phase contrast micrograph of a degenerating primary 
rat hepatocyte monolayer 6 d after seeding; (b) phase contrast 
micrograph of a viable primary rat hepatocyte monolayer main- 
tainext  by 50 #M nafcnopin  for 2 wk; (c) phase contrast micrograph 
of a degenerating  primary rat hepatocyte monolayer 8 d after with- 
drawal of 50 #M nafenopin. 
Induction of  Apoptosis in FaO Hepatoma Cells 
by TGFfll 
Treatment  of  serum-free  FaO  cultures  with  1-5  ng/ml 
TGF/31 led to a  concentration-dependent induction of cell 
death which was accompanied by detachment of cells from 
the monolayer. For example, in three independent experi- 
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Figure 2.  (a)  Fluorescent micmgraph of a 6-d-old degenerating 
primary hepatocyte monolayer stained with Hoechst 33258. The 
brightly stained condensed nuclei of apoptotic cells (arrows)  can 
be distinguished from diffusely stained viable nuclei; (b) percent- 
age of cells with an apoptotic morphology detected by Hoechst 
33258 staining of primary hepatocyte monolayers cultured in the 
presence of 50 #M nafenopin (o) or the nafenopin solvent DMF 
(e) for 8 d following  establishment. Data points represent the mean 
and standard error of six independent experiments in which at least 
800 cells were countx'A every 2 d. 
ments, a 48-h exposure of FaO cells to TGF/3~ resulted in a 
mean cell loss from the monolayer of 89 %. This cell loss was 
shown  to  be  the  result  of cell  death  by  apoptosis  since 
70-80% of detached ceils, collected at 2-h intervals over the 
course of the experiment, exhibited chromatin condensation 
patterns  characteristic  of  apoptosis  (Fig.  4,  a  and  b). 
Moreover, gel electrophoresis of DNA from these detached 
cells  revealed  a  DNA  =ladder"  indicative  of  the  inter- 
nucleosomal DNA cleavage reported for apoptosis in many 
cell  types  (Fig.  4  c).  The  TGF/3~ solvent,  HC1,  had  no 
effect on FaO viability. 
Effect of Nafenopin on TGF(3rinduced FaO Apoptosis 
Co-addition of 50 ~tM nafenopin to FaO cultures treated with 
1-5 ng/ml TGF/3t significantly increased the number of via- 
ble cells that remained attached to the monolayer above the 
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Figure 3.  Percentage  of apoptotic  cells  detected in hepatoeyte 
monolayers treated with TGFIS~ (5 ng/ml) in the presence of 50 
#M nafenopin (n) or 0.25 % vol/vol of the nafenopin solvent DMF 
(=).  Data points are expressed as a percentage of TGF/5~-treated 
controls and represent the mean and standard error of three inde- 
pendent experiments in which at least 800 cells were counted at one 
timepoint per day. 
number counted in cultures treated with TGFjS~ alone (p < 
0.05). For example, Fig. 5 a  shows the percent increase in 
viable cell number induced by the co-addition of nafenopin 
in cultures treated with TGF~1 (1 ng/ml). This increase rep- 
resented a rescue of 10-20% of total cells from death. No 
significant increase in viable cell number was seen in DMF 
solvent-treated control cultures. The increase in viable cell 
number detected in the presence of nafenopin was associated 
with a significant decrease in the rate of detachment of ceils 
(Fig.  5 b). 
Effect of  Nafenopin on FaO Apoptosis Induced by 
D  NA-damaging Agents 
Treatment of FaO cells with 10 #M etoposide led to rapid 
cell loss from the monolayer, with 63 % cell death after 48 
h. Similarly, treatment with 1 mM hydroxyurea resulted in 
84%  detachment  and  cell  death  at  48  h.  In  both  cases, 
detached cells collected at 2-h intervals exhibited chromatin 
condensation and non-random DNA fragmentation patterns 
typical of apoptosis. 24 h after addition of 10 #M etoposide 
48 % of  detached cells exhibited chromatin condensation pat- 
terns  typical  of  apoptosis,  as  revealed  by  AO  staining, 
whereas  only  10%  of detached cells  were permeable  to 
trypan blue. The corresponding values for cells detaching af- 
ter 1 mM hydroxyurea treatment were 37 and 4%, respec- 
tively. In contrast to the results of corresponding experi- 
ments using TGF31, the presence of 50 #M nafenopin in 
hydroxyurea-  and  VP-16-treated  FaO  cultures  had  no 
significant effect on the viable cell number. (Fig. 6, a and b). 
Discussion 
The promotion of tumorigenic lesions occurs not only by 
sustained hyperplasia but also by suppression of apoptosis 
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lowing  treatment  with  5  ng/ml  TGF/~.  (Apoptotic  cells  which 
detached  from the monolayer were collected 2 h after addition of 
fresh medium to the flask); (c) agarose gel electrophoresis of DNA 
from attached (lane 2) and detached  (lane 3) FaO cells 24 h after 
addition of TGF~. Lane 1 contains HaelIl DNA markers. 
(8).  Considerable emphasis  has  been  placed  on  investigating 
the importance of increased mitogenesis in peroxisome 
proliferator-induced  hepatocarcinogencsis,  but few studies 
have addressed the role  of suppression of apoptosis,  for 
which  little  direct  evidence  exists.  The  peroxisomc  prolifera- 
tor  nafenopin  has  been  reported  to  inhibit  apoptosis  during 
the  liver  involution  that  follows  withdrawal  of  the  tumor  pro- 
rooter  cyproterone  acetate  (4).  However, in  view  of  the  short 
half-life  of  apoptotic  hepatocytes  in  vivo,  it  is  difficult  to  de- 
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Figure 5.  (a) Effect of 50 ~M nafenopin on FaO cell viability in 
the presence of 1 ng/ml TGFB~; (D) TGF~I +  50 t~M nafenopin; 
(m) nafenopin solvent DMF control (0.25 % vol/vol). Data points 
represent the mean and standard error of five independent experi- 
ments in which the number of viable cells remaining attached after 
TGF/31 addition  were counted at one timepoint per day.  Results 
are presented as a percentage of the cell number in cultures treated 
with TGF/3~ alone.  (b) Effect of 50 ~,M nafenopin on the detach- 
ment of FaO cells  from the monolayer following treatment  with 
1 ng/ml TGF/5~. (-) Untreated  control;  (n)  1 ng/ml TGF/5~ (e) 
TGF/51  +  DMF (nafenopin solvent 0.25%  vol/vol);  (o) TGF/31 
+  50/~M nafenopin. Data points represent the mean and standard 
error of three  independent  experiments  in which  the number of 
detached ceils was counted at 2-h intervals for 30 h after drug addi- 
tion. Results are presented as a cumulative percentage of the total 
cell number on addition of TGF/~,. 
termine accurately the level of apoptosis occurring at any 
one  particular  time.  Further  elucidation  of the  effect of 
peroxisome proliferators on liver apoptosis would be facili- 
tated by the use of in vitro model systems that can be more 
readily manipulated. We have previously validated FaO as a 
suitable cell type for this purpose (1). In this study we exam- 
ined the effect of nafenopin on apoptosis using both FaO cells 
and monolayer cultures of primary rat hepatocytes. 
We have shown here that nafenopin reversibly maintains 
the viability of primary rat hepatocytes for at least 6 wk. In- 
terestingly,  hepatocyte  cultures  can  be  maintained  by 
nafenopin for as long as 18 mo (C. Elcombe, personal com- 
munication).  In the absence of nafenopin,  hepatocyte cul- 
tures degenerate within 8 d of their establishment. We de- 
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Figure 6. Effect of 50 #M nafenopin on FaO cell viability in the 
presence of (a) 10/~M etoposide and (b) 1 mM hydroxyurea. Data 
points represent the mean and standard error of three independent 
experiments in which the number of  viable cells remaining  attached 
after drug addition was counted at one timepoint per day; (I) con- 
trol; (n) etoposide (a) or hydroxyurea (b); (o) etoposide (a) or 
hydroxyurea  (b) + 50 #M nafenopin; (e) etoposide (a) or hydroxy- 
urea (b)  +  DMF (nafenopin solvent) (0.25% vol/vol). 
tected cells with condensed and fragmented chromatin in 
these  degenerating monolayers indicating that hepatocyte 
cell death occurs via apoptosis.  Only a  small percentage 
(<1%) of apoptotic cells was identified in the monolayer at 
any one timepoint, reflecting both the relatively slow rate of 
culture degeneration and the detachment of degenerating he- 
patocytes from the monolayer. The low percentage of apop- 
totic cells detected also mirrors the situation in vivo where, 
• even during the rapid liver regression that follows withdrawal 
of tumor promoters, only a very small percentage of hepato- 
cytes  exhibit  chromatin  condensation patterns  typical of 
apoptosis at any one timepoint (3, 4). Despite this, nafeno- 
pin-treated hepatocyte cultures exhibited significantly lower 
levels of apoptosis at any one time than DMF solvent-treated 
controls. Our results suggest that maintenance of hepatocyte 
viability by nafenopin in vitro is a result of the suppression 
of hepatocyte apoptosis. While it is tempting to speculate 
that the hepatocarcinogenicity of peroxisome proliferators 
such as nafenopin may stem, in part, from this ability to sup- 
press apoptosis, more detailed investigations are required in 
order to validate this hypothesis. 
TGF/3~ is a negative regulator of liver growth, implicated 
in the control of liver homeostasis (2).  Recent studies have 
indicated that,  in addition to  inducing apoptosis  in vivo 
and in vitro, cytoplasmic TGF/~ latent protein is also in- 
creased in apoptotic hepatocytes (6).  Although it is not yet 
clear whether this upregulation is controlled at the pre- or 
posttranslational level,  it has  been proposed  that TGF/3~ 
may be involved in the induction of liver apoptosis (6). Ac- 
cording to this proposal, cells which sustain some form of 
damage would exhibit elevated cytoplasmic levels of TGFB~ 
protein, either by enhanced synthesis or increased uptake of 
TGF/31 from other cells, and would consequently become 
programmed to die by apoptosis. The ability of nafenopin 
to block TGF/3~-induced cell death would thus provide a 
mechanism by which pre-neoplastic cells could survive long 
enough to accumulate additional transforming mutations. 
This hypothesis is supported by results from our studies of 
the effect of nafenopin on TGF/3m-induced hepatocyte and 
FaO cell death. In the absence of nafenopin, hepatocyte de- 
generation occurred within 48 h of TGF/3~ treatment. The 
rapid onset of cell death was reflected in the increased per- 
centage of  apoptotic cells (3-8 %) identified in the monolayer 
at any one timepoint. TGFBI also rapidly induced FaO cell 
death which was accompanied by detachment of cells from 
the monolayer. In contrast to detached primary hepatocytes, 
which were always highly degraded, detached FaO cells ini- 
tiaUy excluded trypan blue and exhibited chromatin conden- 
sation and non-random DNA fragmentation patterns typical 
of apoptosis.  In  both  cell  systems,  the  level  of TGF/3~- 
induced apoptosis was reduced significantly by co-addition 
of nafenopin. Interestingly, nafenopin did not prevent totally 
TGF/3~-induced hepatocyte or  FaO  cell death.  Neverthe- 
less, suppression of cell death in only a small percentage of 
hepatocytes in vivo could be relevant to hepatocarcinogene- 
sis, particularly if any surviving cells have previously sus- 
tained genetic mutations. The prolonged viability of these 
potentially tumorigenic cells could allow the accumulation 
of further transforming lesions, and ultimately the develop- 
ment of liver tumors. 
Our studies demonstrate that the ability of nafenopin to 
protect liver cells from chemically induced apoptosis is de- 
pendent on the nature of the apoptotic stimulus. Both the 
topoisomerase II inhibitor, etoposide, and the antimetabo- 
lite, hydroxyurea, rapidly induced cell death in FaO cells. 
This cell death was shown to occur predominantly via apop- 
tosis; there was no evidence of necrotic cell death as defined 
by morphology and the low percentage of cells with plasma 
membranes permeable to trypan blue.  Etoposide induces 
protein-associated DNA double strand breaks and hydroxy- 
urea, by preventing the synthesis of DNA bases, indirectly 
damages DNA resulting in single strand breaks. The onset 
of FaO apoptosis induced by these DNA damaging agents 
was not inhibited or retarded by co-addition of nafenopin. A 
possible explanation for this is that the extent of cellular 
damage following exposure to these genotoxic agents is too 
extreme to be prevented by nafenopin. Alternatively, it may 
be that peroxisome proliferators such as nafenopin interfere 
with specific cell death signals with the result that only cer- 
tain forms of cellular damage can be prevented. 
The Journal of Cell Biology, Volume 125,  1994  202 It is improbable that one mechanism alone is responsible 
for peroxisome proliferator-induced  hepatocarcinogenesis. 
It is more likely that a number of different processes work 
in tandem to promote pre-neoplastic liver cells. While the 
exact relationship  between these different mechanisms  re- 
mains speculative, the results of this paper certainly give fur- 
ther support to the theory that suppression of apoptosis may 
be, at least partially, responsible for the hepatocarcinogenic 
nature of this important class of non-genotoxic carcinogens. 
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